BACKGROUND: Components of the insulin-like growth factor (IGF) system have been associated with several cancers, but very few studies are available for ovarian cancer. METHODS: A case-control study conducted between 1999 and 2003 in Italy, including a total of 59 women with incident, histologically confirmed ovarian cancer and 108 controls admitted to the same hospital network as cases, for acute non-neoplastic diseases. All subjects were interviewed using a validated questionnaire. RESULTS: After adjustment for potential confounders, the multivariate odds ratios for the highest versus the lowest tertile of various IGF components were 0.6 (95% confidence interval, CI: 0.2-1.4) for free IGF-I, 0.4 (CI: 0.1-1.5) for total IGF-I, 2.6 (CI: 0.9-6.9) for IGF-binding protein (IGFBP)-1, and 0.2 (CI: 0.0-0.6) for IGFBP-3. CONCLUSIONS: This study suggests a protective role of IGFBP-3 and a positive association of IGFBP-1 with ovarian cancer. The complex role of the IGF system in ovarian carcinogenesis deserves further clarification.
BACKGROUND: Components of the insulin-like growth factor (IGF) system have been associated with several cancers, but very few studies are available for ovarian cancer. METHODS: A case-control study conducted between 1999 and 2003 in Italy, including a total of 59 women with incident, histologically confirmed ovarian cancer and 108 controls admitted to the same hospital network as cases, for acute non-neoplastic diseases. All subjects were interviewed using a validated questionnaire. RESULTS: After adjustment for potential confounders, the multivariate odds ratios for the highest versus the lowest tertile of various IGF components were 0.6 (95% confidence interval, CI: 0.2-1.4) for free IGF-I, 0.4 (CI: 0.1-1.5) for total IGF-I, 2.6 (CI: 0.9-6.9) for IGF-binding protein (IGFBP)-1, and 0.2 (CI: 0.0-0.6) for IGFBP-3. CONCLUSIONS: This study suggests a protective role of IGFBP-3 and a positive association of IGFBP-1 with ovarian cancer. The complex role of the IGF system in ovarian carcinogenesis deserves further clarification.
Authors: Brian Nolen; Liudmila Velikokhatnaya; Adele Marrangoni; Koen De Geest; Aleksey Lomakin; Robert C Bast; Anna Lokshin Journal: Gynecol Oncol Date: 2010-03-24 Impact factor: 5.482
Authors: Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04-01 Impact factor: 4.254